Cover Image
市場調查報告書

成長/分化因素8 (肌肉生長抑制素/GDF-8):開發平台分析

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363561
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
成長/分化因素8 (肌肉生長抑制素/GDF-8):開發平台分析 Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 66 Pages
簡介

本報告提供全球各國的增生/分化因素8 (肌肉生長抑制素或GDF-8) 治療藥的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

成長/分化因素8 (肌肉生長抑制素/GDF-8)的概要

治療藥的開發情形

  • 臨床實驗的各階段
  • 各治療領域
  • 各症狀

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

在各企業開發中的治療藥

治療藥的評估

  • 單劑治療藥/並用治療藥的情況
  • 各作用機制
  • 各投藥法
  • 各分子類型

開發治療藥的企業

  • Acceleron Pharma, Inc.
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Milo Biotechnology LLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Scholar Rock, Inc.

藥物簡介

  • AAV1-forisutachin
    • 產品概要
    • 作用機制
    • 研究開發 (R&D)的發展情形
  • AAV9-forisutachin
  • ACE-083
  • ACE-2494
  • ACE-2798
  • DMD、貝克氏肌肉萎縮症 (MD) 的肌肉生長抑制素抑制用反義寡核苷酸
  • ATA-842
  • BMS-986089
  • domagrozumab
  • landogrozumab
  • luspatercept
  • OSX-200
  • SRK-015
  • trevogrumab

開發暫停的產品

開發中止的產品

值得注意的最新趨勢、新聞稿 (共15件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1017TDB

Summary:

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGFB) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 7 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Genetic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders and Oncology which include indications Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Sarcopenia, Anemia, Becker Muscular Dystrophy, Charcot-Marie-Tooth Disease Type I, Crohn's Disease (Regional Enteritis), Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Inclusion Body Myositis (IBM), Insulin Resistance, Muscle Atrophy, Myelodysplastic Syndrome, Myelofibrosis, Sickle Cell Disease, Spinal Muscular Atrophy (SMA) and Thalassemia.

The latest report Growth Differentiation Factor 8 - Pipeline Review, H2 2017, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
  • The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
    • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
    • Acceleron Pharma Inc
    • Amgen Inc
    • Bioleaders Corp
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc
    • Regeneron Pharmaceuticals Inc
    • Sarepta Therapeutics Inc
    • Scholar Rock Inc
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
    • ACE-083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACE-2494 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACE-2798 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATA-842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLS-ILB-MD1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • domagrozumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • luspatercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-2477 + trevogrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-6206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRK-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trevogrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 01, 2017: Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease
      • Jul 10, 2017: Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium
      • Jun 28, 2017: Scholar Rock to Develop SRK-015 to Improve Muscle Function in Patients with Spinal Muscular Atrophy
      • Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association
      • Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association
      • Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia
      • May 30, 2017: Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF- 06252616) in Duchenne Muscular Dystrophy
      • May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association
      • May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes
      • Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program
      • Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes
      • Mar 16, 2017: Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease and Host Educational Webinar
      • Dec 22, 2016: Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy
      • Dec 05, 2016: Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology
      • Dec 04, 2016: Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Acceleron Pharma Inc, H2 2017
  • Pipeline by Amgen Inc, H2 2017
  • Pipeline by Bioleaders Corp, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Pipeline by Sarepta Therapeutics Inc, H2 2017
  • Pipeline by Scholar Rock Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top